Table 1.
Clinicopathological features and results of studied parameters in all groups.
| Character | Healthy control group (HC; n = 54) | Benign Prostate Hyperplasia (BPH; n = 69) | Prostate Cancer (PCa; n = 71) | P value |
|---|---|---|---|---|
|
Age (years) Mean ± SD Median (Range) |
60.75 ± 3.47 60.40 (55.5–68.0) |
61.89 ± 4.36 63.0 (53.0–72.20) |
61.55 ± 4.28 62.4 (53.0–72.0) |
0.256 |
|
BMI Mean ± SD Median (Range) |
26.86 ± 2.07 26.81 (23.81–33.2) |
26.68 ± 1.96 26.0 (24.5–31.4) |
27.16 ± 2.11 26.8 (25.1–32.2) |
0.768 |
|
uPA (ng/mL) Mean ± SD Median (Range) |
0.46 ± 0.37 0.42 (0.01–1.8) |
0.68 ± 0.2 0.66 (0.4–1.7) |
0.83 ± 0.13 0.88 (0.54–1.1) |
≤0.001** |
|
PSA (ng/mL) Mean ± SD Median (Range) |
6.6 ± 1.1 6.4 (4.67–9.45) |
6.7 ± 1.2 6.75(4.01–9.65) |
6.8 ± 1.34 6.67(4.12–9.82) |
0.954 |
|
fPSA (ng/mL) Mean ± SD Median (Range) |
1.5 ± 0.61 1.56 (0.48–2.55) |
0.95 ± 0.35 0.89 (0.52–2.54) |
0.9 ± 0.32 0.87 (0.43–2.23) |
≤0.001** |
|
%fPSA Mean ± SD Median (Range) |
0.23 ± 0.09 0.22 (0.08–0.52) |
0.15 ± 0.07 0.13 (0.08–0.4) |
0.14 ± 0.06 0.12 (0.05–0.45) |
≤0.001** |
|
P2PSA (pg/mL) Mean ± SD Median (Range) |
13.97 ± 2.6 13.43 (8.98–19.78) |
14.46 ± 1.3 14.7(11.34–17) |
16.15 ± 2.5) 16.97(10.78–22.51) |
≤0.001** |
|
%P2PSA Mean ± SD Median (Range) |
2.13 ± 0.59 2.07(1.09–4.0) |
2.23 ± 0.44 2.21(1.43–3.42) |
2.47 ± 0.68 2.42(1.35–4.7) |
≤0.001** |
|
PHI Mean ± SD Median (Range) |
27.52 ± 13.85 24 (13.18–94.25) |
42.51 ± 11.12 44.86(13.16) |
51.56 ± 17.69 47.67(16–96.18) |
≤0.001** |
|
Biopsy gleason score categories n (%) <7 ≥7 |
NA |
NA |
17 (23.9%) 54 (76.05) |
|
|
Clinical Stage n (%) Early: cT1; cT2a Late: cT2b,c; T3 |
NA |
NA |
25 (35.21%) 46 (64.78%) |
|
|
LN extension n (%) +ve −ve |
NA | NA |
47 (66.21%) 24(33.8% |
|
|
Metastasis n (%) M0 M1 |
NA |
NA |
8 (11.27%) 63(88.73%) |
|
|
RPSeminal vesicle involvement&, n (%) +ve −ve |
NA |
NA |
37(58.73%) 26(41.26%) |
|
|
RPSurgical margin&, n (%) R0 R1 |
NA |
NA |
35(55.56%) 28(44.44%) |
BMI, body mass index; BPH, benign prostate hyperplasia; %fPSA, percentage of free PSA to total PSA; p2PSA, [-2]proPSA; %p2PSA, percentage of [-2]proPSA to free PSA; PCa, prostate cancer; PHI, Prostate Health Index; PSA, prostate-specific antigen, RP, Radical prostatectomy, ** = p value < 0.001.